The tumor microenvironment creates powerful obstacles for cancer immunotherapy by limiting the expansion of local tumor-specific T lymphocytes, preventing T-cell penetration and the killing of tumor-specific targets. Therefore, therapeutic targeting of the tumor microenvironment combined with immunotherapy is a logical and attractive approach. We have shown that both chemotherapy and treatment targeted to mutated BRAF increased the susceptibility of melanoma cells to the cytotoxic effect of T cells through a dramatic perforin-independent increase in permeability to granzyme B (GrzB) released by activated cytotoxic T cells (CTL). Our data strongly suggested that this effect was mediated via up-regulation of the expression of mannose-6-phosphate receptors (MPR) on the surface of tumor cells while undergoing autophagy. When combined with chemo- or targeted therapy, CTLs raised against specific antigens were able to induce apoptosis in neighboring tumor cells that did not express those antigens, creating a bystander effect. Our preliminary experiments demonstrated that BRAF inhibitors with potent anti-tumor activity against melanoma induced up-regulation of MPR in BFAF mutated melanoma cells, suggesting that they might provide a potent bystander effect with adoptive cell therapy. In the current proposal we will further explore the mechanisms by which targeted and chemotherapeutic agents alter tumor susceptibility to T cell destruction, and propose two clinical trials. In the first trial we will biopsy accessible tumors from patients receiving either a targeted BRAF agent or a chemotherapeutic drug before and after treatment and determine if MPR, markers of autophagy and GrzB are increased on melanoma cells, and when after initiation of treatment increases in these markers can be measured. These findings will then be translated to a phase II trial of the BRAF inhibitor vemurafenib combined with adoptive cell therapy with tumor infiltrating lymphocytes (TIL) and IL-2 after lymphdepletion. This trial will test whether targeted therapy combined with TIL will increase the clinical efficacy of the immunotherapy and result in a higher proportion of patients who do not drop out before they receive their TIL.

Public Health Relevance

Adoptive cell therapy with TIL is a promising therapy for melanoma, but is practical only for a limited cohort of patients with stage IV disease. In this project we propose preclinical experiments and two clinical trials to increase the efficacy of this treatment and decrease the likelihood that patients will drop out prior to receiving their TIL, increasing the applicability of this technology to patients with stage IV melanoma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Prieto-Granada, Carlos; Castner, Nicholas; Chen, Ann et al. (2018) Behavior of Cutaneous Adnexal Malignancies: a Single Institution Experience. Pathol Oncol Res :
Abate-Daga, Daniel; Ramello, Maria C; Smalley, Inna et al. (2018) The biology and therapeutic management of melanoma brain metastases. Biochem Pharmacol 153:35-45
Konno, Hiroyasu; Yamauchi, Shota; Berglund, Anders et al. (2018) Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene 37:2037-2051
Eroglu, Zeynep; Ozgun, Alpaslan (2018) Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma. Expert Opin Orphan Drugs 6:545-551
Zhu, Genyuan; Brayer, Jason; Padron, Eric et al. (2018) OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A 93:982-986
Zhu, Genyuan; Nemoto, Satoshi; Mailloux, Adam W et al. (2018) Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. Front Immunol 9:1609
Ramello, Maria C; Haura, Eric B; Abate-Daga, Daniel (2018) CAR-T cells and combination therapies: What's next in the immunotherapy revolution? Pharmacol Res 129:194-203
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88
Saglam, Ozlen; Naqvi, Syeda M H; Zhang, Yonghong et al. (2018) Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience. Melanoma Res 28:586-591

Showing the most recent 10 out of 62 publications